Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated ...

A multiomic approach for detecting clinically significant prostate cancer in seminal fluid: Results from a large multicenter clinical study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health ...

177Lu-PSMA-617 consolidation therapy post docetaxel in patients with de-novo high-volume metastatic hormone-sensitive prostate cancer: A randomized, phase 2 trial. Outcomes of initial vs delayed ...

With early detection of prostate cancer recognised as a critical part in reducing the disease’s mortality rate, PanGIA ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

Johnson & Johnson has reported data from a Phase I trial of pasritamig for metastatic castration-resistant prostate cancer ...

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

Scientists say they have worked out a machine learning method with the ability to provide close to precise survival estimates of patients afflicted ...

In this pilot trial, acupuncture produced greater reductions in nocturia (waking up 1 or more times to urinate) relative to ...

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

Doctors examine a tumor in several different ways to determine whether a cancer is aggressive – and what kinds of treatments, ...